Cargando…
Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer
SIMPLE SUMMARY: Individualized diagnostics approaches in modern cancer therapy require predictive and prognostic biomarkers that are easily accessible and stratify patients for optimal and individualized treatment. Pancreatic ductal adenocarcinoma (PDAC) is still a life-threatening disease mainly be...
Autores principales: | Mehdorn, Anne-Sophie, Gemoll, Timo, Busch, Hauke, Kern, Katharina, Beckinger, Silje, Daunke, Tina, Kahlert, Christoph, Uzunoglu, Faik G., Hendricks, Alexander, Buertin, Florian, Wittel, Uwe A., Sunami, Yoshiaki, Röcken, Christoph, Becker, Thomas, Sebens, Susanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562670/ https://www.ncbi.nlm.nih.gov/pubmed/36230528 http://dx.doi.org/10.3390/cancers14194605 |
Ejemplares similares
-
Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma
por: Beckinger, Silje, et al.
Publicado: (2023) -
Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control
por: Heckl, Steffen M., et al.
Publicado: (2021) -
Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma
por: Daunke, Tina, et al.
Publicado: (2023) -
Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells
por: Hellmold, Dana, et al.
Publicado: (2023) -
The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection
por: Miarka, Lauritz, et al.
Publicado: (2019)